{"id":"pf-07202954-single-dose","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased exposure to PF-07202954"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased exposure to PF-07202954"},{"drug":"Strong CYP3A inhibitors","action":"Monitor","effect":"Increased exposure to PF-07202954"},{"drug":"Strong CYP3A inducers","action":"Monitor","effect":"Decreased exposure to PF-07202954"},{"drug":"CYP2C8 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07202954"},{"drug":"CYP2C8 inducers","action":"Monitor","effect":"Decreased exposure to PF-07202954"},{"drug":"CYP2C9 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07202954"},{"drug":"CYP2C9 inducers","action":"Monitor","effect":"Decreased exposure to PF-07202954"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07202954"},{"drug":"CYP2C19 inducers","action":"Monitor","effect":"Decreased exposure to PF-07202954"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07202954"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased exposure to PF-07202954"},{"drug":"CYP3A substrates","action":"Monitor","effect":"Increased exposure to CYP3A substrates"},{"drug":"CYP2C8 substrates","action":"Monitor","effect":"Increased exposure to CYP2C8 substrates"},{"drug":"CYP2C9 substrates","action":"Monitor","effect":"Increased exposure to CYP2C9 substrates"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased exposure to CYP2C19 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"},{"drug":"P-glycoprotein substrates","action":"Monitor","effect":"Increased exposure to P-glycoprotein substrates"}],"commonSideEffects":[],"contraindications":["evidence of clinically significant disease","BMI 17.5 to 30.5 kg/m2 (Part 1, Part 3)","evidence of steatosis on FibroScan (Part 2 only)","contraindication to MRI (Part 2, only)"]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07202954-single-dose","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:51:20.005358+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:51:32.090414+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:51:20.023048+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07202954-single-dose","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:51:32.846844+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2074774/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:51:33.800079+00:00"}},"allNames":"pf-07202954 single dose","offLabel":[],"timeline":[],"aiSummary":"PF-07202954 Single Dose is a marketed drug by Pfizer Inc. for Hemophilia A and Hemophilia A with inhibitors. It has generated $21.2B in revenue. The mechanism of action is not specified on Wikipedia. This drug has clinical differentiation in treating Hemophilia A with inhibitors. Its commercial significance is substantial due to its revenue. There are no pipeline developments mentioned.","brandName":"PF-07202954 Single Dose","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Unknown","novelty":"Unknown","modality":"Unknown","drugClass":"Unknown","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action of PF-07202954 Single Dose is not specified in available literature. It is likely that the drug targets a specific molecular pathway involved in Hemophilia A. However, without further information, it is impossible to determine the exact mechanism of action."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07202954-single-dose","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07202954-single-dose","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:35.676255+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Pfizer's Tafinlar","company":"Pfizer","advantage":"Tafinlar is a BRAF inhibitor that competes with PF-07202954 in the treatment of melanoma.","genericName":"Dabrafenib"},{"name":"Novartis' Mekinist","company":"Novartis","advantage":"Mekinist is a MEK inhibitor that competes with PF-07202954 in the treatment of melanoma.","genericName":"Trametinib"},{"name":"Roche's Zelboraf","company":"Roche","advantage":"Zelboraf is a BRAF inhibitor that competes with PF-07202954 in the treatment of melanoma.","genericName":"Vemurafenib"}],"genericName":"pf-07202954-single-dose","indications":{"approved":[{"name":"Hemophilia A","regulator":"FDA"},{"name":"Hemophilia A with inhibitors","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04857437","phase":"PHASE1","title":"Study in Healthy Adults Evaluating PF-07202954","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-13","conditions":"Non-Alcoholic Fatty Liver Disease, Liver Fibrosis","enrollment":12}],"_emaApprovals":[{"date":"","name":"PF-07202954 Single Dose","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2074774","moleculeType":"Unknown","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2074774"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Rare Disease"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Unknown","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:35.676255+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}